m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03815)
Name
ABBV-CX-2029
Status
Phase 1
TTD Drug ID
D58AMF
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Transferrin receptor protein 1 (TFRC)
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Transferrin receptor protein 1 (TFRC) is a therapeutic target for ABBV-CX-2029. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ABBV-CX-2029 through regulating the expression of Transferrin receptor protein 1 (TFRC). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Transferrin receptor protein 1 (TFRC) is a therapeutic target for ABBV-CX-2029. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ABBV-CX-2029 through regulating the expression of Transferrin receptor protein 1 (TFRC). [2], [3]
References
Ref 1 Amelioration of acute myocardial infarction injury through targeted ferritin nanocages loaded with an ALKBH5 inhibitor. Acta Biomater. 2022 Mar 1;140:481-491. doi: 10.1016/j.actbio.2021.11.041. Epub 2021 Dec 5.
Ref 2 Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem. 2007 Sep 21;282(38):27781-91. doi: 10.1074/jbc.M703286200. Epub 2007 Jul 10.
Ref 3 YTHDF1-enhanced iron metabolism depends on TFRC m(6)A methylation. Theranostics. 2020 Oct 26;10(26):12072-12089. doi: 10.7150/thno.51231. eCollection 2020.